Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.60 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30322741 | 1.00 | KMT2A (0.60) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL29537998 | 0.86 | HCRTR1 (0.57) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL14936588 | 0.86 | HCRTR1 (0.57) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL4590566 | 0.85 | LMNA (0.52) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL1644169 | 0.84 | KMT2A (0.51) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL18150837 | 0.84 | MAPT (0.48) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL29665865 | 0.84 | KMT2A (0.51) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL10864261 | 0.84 | MAPT (0.58) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL19308432 | 0.83 | MAPT (0.57) | KMT2AMAPTMEN1LMNAPLIN1 | |
| SCHEMBL4779721 | 0.83 | MAPT (0.57) | KMT2AMAPTMEN1LMNAPLIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153170-B1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | SERVIER LAB (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240351994-A1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | KAERUS BIOSCIENCE LIMITED (GB) | 2024-10-24 | — | — | US | disclosed |
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4153170-A1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | Kaerus Bioscience Limited (GB) | 2023-03-29 | — | — | EP | disclosed |
| CN-115666554-A | Novel Maxi-K potassium channel openers for the treatment of fragile X related disorders | 凯鲁斯生物科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI (FR) | 2004-10-21 | — | — | US | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | disclosed |
| US-6624164-B2 | Solvates and/or hydrates exhibiting affinity for the arginine-vasopressin V1b receptors or for both V1b and V1a 1a receptors. | SANOFI-SYNTHELABO (FR) | 2003-09-23 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SANOFI-AVENTIS (FR) | 2003-07-24 | — | — | US | disclosed |
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
| EP-0386940-A1 | 6-Beta-(alpha-etherified oxymino)-acyl amino penicillins | BEECHAM GROUP PLC (GB) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351994-A1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | KCNN2, KCNN1, KCNJ11 | KMT2A 790/4885MAPT 1739/4885MEN1 596/4885 |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | AVPR2, AVPR1B, AVPR1A | KMT2A 4598/4885MAPT 2384/4885MEN1 779/4885 |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | AVPR1B, AVPR1A, AVPR2 | KMT2A 4311/4885MAPT 1850/4885MEN1 439/4885 |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KMT2A 997/4885MAPT 4744/4885MEN1 769/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | KMT2A 997/4885MAPT 4744/4885MEN1 769/4885 |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | KMT2A 4115/4885MAPT 2716/4885MEN1 253/4885 |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | KMT2A 3824/4885MAPT 1941/4885MEN1 626/4885 |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR2, AVPR1B, AVPR1A | KMT2A 4496/4885MAPT 3101/4885MEN1 804/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | KMT2A 4309/4885MAPT 3026/4885MEN1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.